Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Cancer biologics Market Expected to Grow Between 2025 And 2029?

The market size for cancer biologics has experienced swift growth in the past few years. It is projected to increase from $106.2 billion in 2024 to $117.03 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.2%. The significant growth during the historic period is deduced from the surge in cancer cases, escalated consciousness about cancer biologics, advances in the efficiency and safety of cancer biologics, the sanction of novel cancer biologics, and an expanding endorsement for combination therapy.

What Growth Rate Is Anticipated for the Cancer biologics Market in the Coming Years?

In the coming years, the cancer biologics market is projected to experience robust expansion. The market is anticipated to increase to a value of $168.75 billion in 2029, with a compound annual growth rate (CAGR) of 9.6%. This significant growth during the forecast period can be credited to numerous factors such as broadening indications, combination therapies, real-world proof, gene, and cell therapies. The forecast framework also indicates key trends including progress in biotechnology, personalization of cancer biologics, biobetters and biosimilars, patient support services, and companion diagnostics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

Who Are the Leading Companies in the Cancer biologics Market?

Major companies operating in the cancer biologics market include AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

What Are the Key Drivers of the Cancer biologics Market?

The increasing incidence of chronic ailments is a significant propellant for the growth of the cancer biologics market. These are diseases with a prolonged duration, negatively impacting individuals with disabilities. Cancer ranks high among these chronic diseases. Common types of cancers include breast, lung and bronchus, prostate, colon and rectum, skin melanoma, bladder, non-Hodgkin lymphoma, kidney and renal pelvis, endometrial, leukemia, pancreatic, thyroid, and liver cancers. As per data released by the US-based public health agency Centers for Disease Control and Prevention (CDC) in February 2024, an escalating number of Americans are contending with multiple chronic conditions—42% with two or more, and 12% with five or more. Accordingly, this increasing frequency of chronic diseases is projected to fuel the growth of the cancer biologics market in the foreseeable future.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

What Are the Key Market Segments in the Cancer biologics Industry?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

What Are the Latest Trends in the Cancer biologics Market?

Businesses operating in the cancer biologics market are innovating predictive biomarkers that assist doctors in determining their patients’ treatments by leveraging physiological biomarkers to forecast performance. These predictive biomarkers evaluate tumor progression in patients by inspecting the key causative elements, considering that each patient’s cancer cause varies. Furthermore, these biomarkers are instrumental not just in early cancer diagnosis but also in choosing the most cost-efficient treatment plans, particularly for biologics rooted in gene therapy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

What Are the Key Regional Markets in the Cancer biologics Industry?

The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2563

This Report Delivers Insight On:

1. How big is the cancer biologics market, and how is it changing globally?

2. Who are the major companies in the cancer biologics market, and how are they performing?

3. What are the key opportunities and risks in the cancer biologics market right now?

4. Which products or customer segments are growing the most in the cancer biologics market?

5. What factors are helping or slowing down the growth of the cancer biologics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model